Drug Layering in Heart Failure: Phenotype-Guided Initiation

Area of Science:

• Cardiology
• Pharmacology
• Clinical Medicine

Background:

• Standard treatment for heart failure with reduced ejection fraction (HFrEF) involves sequential drug up-titration in stable patients.
• High rates of cardiovascular death and hospitalization occur shortly after hospital discharge.
• Evidence suggests rapid onset of treatment effects for HFrEF medications within 28 days.

Purpose of the Study:

• To propose a personalized treatment layering strategy for HFrEF based on patient phenotypes.
• To explore early initiation of HFrEF medications to reduce cardiac events.
• To complement existing sequential treatment approaches.

Main Methods:

• Expert opinion proposing treatment layering based on patient phenotypes (heart rate, blood pressure, renal function, electrolytes).
• Consideration of specific patient subgroups with unique treatment initiation needs.
• Integration with existing strategies based on drug efficacy, cardiac disease, and patient preferences.

Main Results:

• Patient phenotyping may guide personalized drug layering for optimal outcomes in HFrEF.
• Early treatment initiation, potentially before full stability or hospital discharge, may offer benefits.
• This approach complements sequential drug administration strategies.

Conclusions:

• Personalized treatment layering based on patient phenotypes is proposed for HFrEF.
• Early initiation of evidence-based medications could further reduce adverse cardiac events.
• Pragmatic clinical trials are needed to validate these phenotyping-guided approaches.